JPMorgan Downgrades Pfizer (PFE) to Neutral

December 11, 2018 5:05 AM

JPMorgan analyst Chris Schott downgraded Pfizer (NYSE: PFE) from Overweight to Neutral with a price target of $46.00.

The analyst cites the valuation for the downgrade following a "strong 2018."

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $43.85 yesterday.

Categories

Analyst Comments Downgrades

Next Articles